Welcome to our dedicated page for NeOnc Technologies Holdings SEC filings (Ticker: NTHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeOnc Technologies Holdings, Inc. (NTHI) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as a Nasdaq-listed issuer focused on central nervous system therapeutics. NeOnc’s filings, including Forms 8‑K and its registration statement on Form S‑1, provide structured insight into its CNS oncology pipeline, corporate transactions and capital structure.
Through recent 8‑K filings, NeOnc has furnished press releases and supporting materials describing updated Phase 1/2a and Phase 2a clinical results for intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma, including radiographic response data, progression-free survival and long-term survival metrics, as well as safety observations. Other 8‑K reports outline U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb development of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors.
Filings also detail material agreements and strategic initiatives, such as a Master Services Agreement with Insights Pharmaceutical Research LLC (IROS) to conduct multi-site clinical trials in the United Arab Emirates, the formation and role of the NuroMENA subsidiary, share exchange transactions, and acquisitions of entities like JandB Holdings, LLC. Additional disclosures cover executive appointments, equity incentive awards, bridge loans, lines of credit and other financing arrangements that support NeOnc’s clinical programs.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly understand key points from lengthy registration statements, 8‑K event descriptions and related exhibits, helping them interpret how clinical data updates, regulatory decisions, financing structures and governance changes may relate to NTHI’s CNS oncology strategy. Real-time updates from EDGAR ensure that new NeOnc filings are incorporated as they become available, enabling efficient review of the company’s ongoing reporting history.
NeOnc Technologies Holdings (NTHI) filed its Q3 2025 10‑Q, reporting a net loss of $8.6 million for the quarter and $46.6 million year‑to‑date. Operating expenses rose on non‑cash items, including $5.0 million in Q3 share‑based compensation and $25.96 million year‑to‑date. Cash and cash equivalents were $1.51 million at September 30, 2025, with a shareholders’ deficit of $11.81 million and accumulated deficit of $97.23 million. The company stated that these conditions raise substantial doubt about its ability to continue as a going concern.
NeOnc completed its Nasdaq listing in March and received $11.64 million from a private placement after effectiveness. It also drew net proceeds of $3.20 million from an equity purchase agreement (447,527 shares) and issued $4.0 million of convertible notes with a 20% original issue discount, later extended once. Current liabilities include an accrued related‑party advisory fee of $3.68 million and a litigation settlement payable of $4.75 million. NIH grants of $400,000 and about $1.01 million were awarded late in the quarter; no related revenue was recognized.
NeOnc Technologies Holdings (NTHI) filed a Rule 424(b)(4) prospectus supplement to its S-1, updating the base prospectus by attaching recent Quarterly and Current Reports. Its common stock trades on Nasdaq as NTHI.
For the quarter ended March 31, 2025, NeOnc reported a net loss of $38,001,987 on revenue of $39,990, driven by $23,073,745 in share-based compensation and an $11,328,565 advisory fee tied to its Nasdaq listing. Cash and cash equivalents were $5,439,210 at quarter-end. The company completed a private placement totaling $11,644,005, released to the company after its registration statement became effective.
Management disclosed substantial doubt about continuing as a going concern. Liquidity tools include a $10.0 million related-party line of credit (with warrants) and a $50.0 million equity purchase agreement; no borrowings or puts were utilized as of March 31, 2025. Shares outstanding were 19,026,776 as of May 9, 2025. The filing references material weaknesses in internal control over financial reporting.
NeOnc Technologies Holdings (NTHI) furnished a Reg FD update announcing updated clinical results from ongoing Phase 1/2a and compassionate care studies of its investigational intranasal agent NEO100 in a 24-patient cohort with recurrent WHO Grade III/IV IDH1‑mutant astrocytoma.
The company also hosted an investor call to discuss the results and provided supporting materials. The press release, investor presentation, and call transcript are furnished as Exhibits 99.1, 99.2, and 99.3. The information under Item 7.01 is furnished, not filed, and is not subject to Section 18 liabilities or incorporation by reference except as specifically stated.
NEONC Technologies Holdings (NTHI): insider equity grant reported. President, Director, and 10% Owner Amir F. Heshmatpour reported acquiring 1,200,000 shares of restricted common stock on 11/06/2025 under the 2023 Equity Incentive Plan. Of these, 600,000 vest on January 2, 2026, with the remaining 600,000 vesting in twelve monthly tranches of 50,000 beginning February 1, 2026.
Following the grant, directly beneficially owned common stock was 2,962,000 shares. Indirect holdings were reported as 256,120 shares by HCWG LLC, 550,000 shares by KIG LLC, and 3,714,020 shares by AFH Holding & Advisory, LLC, with applicable ownership disclaimers noted.
NeOnc Technologies Holdings, Inc. announced it will host an investor conference call and webcast on November 12, 2025 at 9:00 a.m. Eastern Time to present data updates from its ongoing Phase 1/2a NEO100-1 clinical trial and its compassionate use program.
The announcement was furnished under Item 7.01, and a related press release dated November 7, 2025 was attached as Exhibit 99.1.
NeOnc Technologies Holdings (NTHI) announced a leadership change. On October 31, 2025, Dr. Thomas Chen resigned as Chief Executive Officer and became Chief Medical Officer and Chief Scientific Officer, while remaining Vice Chairman. The Board appointed Amir Heshmatpour as Chief Executive Officer effective immediately; he also continues as President and Executive Chairman.
The Company agreed to pay Mr. Heshmatpour
The filing also summarizes prior related-party and financing items: AFH advisory fees of
NeOnc Technologies Holdings, Inc. (NTHI) announced a leadership change at its Middle East subsidiary. His Highness Sheikh Nahyan bin Zayed Al Nahyan will formally assume the role of Executive Chairman of NuroMENA Holdings Ltd., the company’s Middle East unit. The update was communicated via a press release.
The announcement was furnished under Item 7.01 and is not deemed “filed” under the Exchange Act. A copy of the press release is included as Exhibit 99.1.
NeOnc Technologies Holdings, Inc. reported that its previously announced $50 million strategic partnership is now expected to close no later than October 23, 2025, after receiving all required tax identification and regulatory approvals from the United Arab Emirates. This indicates the transaction has cleared key governmental and regulatory hurdles and is approaching completion.
The company shared this update through a press release furnished under a Regulation FD disclosure, meaning the information is being made broadly available to the market but is not treated as filed for liability purposes or automatically incorporated into other securities law documents unless specifically referenced.
NeOnc Technologies Holdings, Inc. has entered into a Master Services Agreement with Insights Pharmaceutical Research LLC (IROS), a UAE-based contract research organization affiliated with Group 42 Holding Ltd. and Mubadala Investment Company PJSC. Under this agreement, IROS will run clinical trials in the UAE for NeOnc, handling regulatory submissions, site selection and management, monitoring, data management and trial reporting in line with Good Clinical Practice and UAE/FDA rules.
The first work order covers a multi-site, randomized Phase 2b/3 study of intranasal NEO100 in patients with progressive or recurrent Grade III astrocytomas and glioblastoma multiforme, with an estimated budget of about $2.4 million in service fees and $0.1 million in pass-through costs, paid in four milestone-based installments. NeOnc keeps all rights to the clinical data, intellectual property and regulatory filings, and plans to transfer the MSA to its controlled UAE subsidiary, NuroCure, once that entity is incorporated.
NeOnc Technologies Holdings, Inc. filed a current report describing a regulatory milestone for its lead program. The company announced that the U.S. Food and Drug Administration has authorized it to proceed with Phase IIa/IIb of its NEO212-01 clinical trial, indicating clearance to advance this investigational therapy into the next stage of human testing. The update was communicated through a press release furnished as an exhibit to the report rather than filed for liability purposes under the securities laws.
FAQ
What is the current stock price of NeOnc Technologies Holdings (NTHI)?
What is the market cap of NeOnc Technologies Holdings (NTHI)?
